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Natriuretic peptides (NP) are volume sensitive
hormones that have attracted the interest of inve-
stigators in the setting of heart failure (HF) during
recent years. NP levels may reflect the end-diasto-
lic wall stress which is elevated by both increasing
filling pressure and left ventricular dilatation.
Brain natriuretic peptide (BNP) and N-terminal pro
B-type natriuretic peptide (NT-proBNP) have a ne-
gative correlation with left ventricular systolic func-
tion and have been proposed as diagnostic tools and
prognostic markers in HF patients [1, 2]. Cardio-
vascular guidelines recommend that both peptides
should be considered equal [1].
The value of BNP and NT-proBNP
in daily diagnostic practice
Many studies have shown that the measure-
ment of BNP and NT-proBNP can distinguish pa-
tients with acutely decompensated HF from those
who present with other causes of dyspnea. The BNP
threshold level of 100 pg/mL was based on studies
of patients with acutely decompensated HF rather
than chronic HF. However, the NP levels cannot
be used to differentiate systolic from diastolic dys-
function; their measurement might be used to find
patients with HF in the general community, to
quantify symptoms and functional limitations, and
to predict the risk of cardiovascular events. In the
interpretation of plasma NP levels several factors
such as age, sex, renal function, cardiac rhythm,
obesity, and drug therapy should be taken into ac-
count [3–5]. The clinical application of both NPs
exceeds their use as rule-out blood tests for HF.
The value of BNP and NT-proBNP
in quantifying functional capacity
 During recent years the parameters of cardio-
pulmonary exercise have provided the more objec-
tive assessment of functional capacity in patients
with HF than New York Heart Association (NYHA)
class. However, there is a limited relation between
maximal oxygen consumption and parameters of se-
verity of HF, such as NYHA functional class and left
ventricular ejection fraction (LVEF). It has recently
been suggested that plasma BNP levels are related
to VO2 at peak of exercise and could be a predictor
of impaired exercise capacity in patients with HF
[6–8]. In this issue of ”Cardiology Journal”, Koç et
al. [9] present the usefulness of NT-pro BNP for the
prediction of low functional capacity (FC), decreased
LVEF, and the identification of patients at highest
risk of future cardiovascular events. In the asses-
sment of FC, the exercise test has been used, and
the cutoff value for NT-proBNP in the prediction
of FC < 5 METs was defined [9]. The relationship
between NP and the functional capacity may be
explained by the fact that patients with an elevated
rest left ventricular diastolic pressure are prone to
the marked elevation of the capillary wedge pres-
sure during exercise.
What is the role of BNP and NT-proBNP
in predicting low LVEF?
Echocardiographic LVEF is an arbitrary and ob-
jective marker of cardiac dysfunction and is helpful
to identify patients with poor prognosis. Although
echocardiography remains a gold standard for the
detection of left ventricular dysfunction, NPs are
attractive for screening for left ventricular systolic
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dysfunction in asymptomatic populations with sub-
clinical disease [10]. In the study of Koç et al. [9],
a strong negative correlation between NT-proBNP
and ejection fraction was found and an NT-proBNP
cut-off value was defined for the prediction of LVEF
< 30% in a population with a broad spectrum of
NYHA classes (I–IV). Hence, it could be supposed
that NP might replace ejection fraction in daily prac-
tice. Hetmanski et al. [11] measured plasma BNP
values and compared them to echocardiographic
measurements of left ventricular function in 653
prescribed loop diuretic patients in a large commu-
nity based population. The study demonstrated a si-
gnificant correlation between plasma BNP and
echocardiographic ejection fraction. However, the
area under the ROC curve was 0.587 indicating poor
sensitivity and specifity in diagnosis of HF in the
general community, which is supported by the wide
range of values of BNP. Tang et al. [12] reported
that in symptomatic patients up to 21% have levels of
BNP below the threshold criteria value < 100 pg/mL.
The suggested explanation is that patients with end-
-stage HF may have very low NP levels because the
ability of their ventricles to release NP may have
become exhausted; another explanation could be
that they respond to the optimal therapy. The in-
traindividual heterogeneity of plasma BNP value
might affect our ability to use a single “cutoff” va-
lue as a target to guide therapy. Hence, there is
a lack of evidence supporting the concept that NP
may replace ejection fraction. The complex evalu-
ation joining BNP and imaging test seems to be
a rational approach.
The value of NP in the evaluation of
left ventricular diastolic dysfunction
Left ventricular diastolic dysfunction is a com-
mon finding in patients with left ventricular systo-
lic dysfunction, and a restrictive filling pattern es-
timated by Doppler echocardiography is associated
with an increased mortality rate. BNP can be con-
sidered the most powerful predictor of the restric-
tive pattern in patients with severe left ventricular
dysfunction [13, 14].
The severity of diastolic dysfunction is corre-
lated to the increased levels of both BNP and
NT-proBNP. It is interesting that in the study by
Koç et al. [9] linear regression analysis showed that
left atrial end-diastolic dimension and NT-proBNP
are the most significant predictors for left ventri-
cular E/A ratio, reflecting the restrictive filling pat-
tern. The restrictive filling pattern is associated
with increasing left ventricular end-diastolic and left
atrial pressure. Furtermore Lubien et al. [15] repor-
ted that BNP can detect the presence of diastolic
abnormalities even in patients with normal systo-
lic function, but they were not able to differentiate
the various diastolic filling patterns.
The use of BNP and NT-proBNP
as prognostic markers in heart failure
The prognostic value of risk factors such as
ejection fraction, complex arrhythmia, and heart
failure symptoms is limited [16]. There are several
data regarding prognostic implications of different
neurohormonal markers, including BNP and
NT-proBNP. NT-proBNP was superior to LVEF in
predicting mortality and heart failure occurrence in
the Australia/New Zealand Heart Failure Study and
in the COPERNICUS NT-proBNP substudy [17, 18].
In accordance with those studies, the current pa-
per by Koç et al. [9] indicated that among several
variables only NT-proBNP, left ventricular mass
index, and resting heart rate were independent pre-
dictors of future cardiovascular events, but not
LVEF. The authors also defined the cut-off value
of NT-proBNP for the prediction of cardiovascular
events. However, to define cutoff points for quan-
tifying the severity of HF and for risk stratification,
further studies based on large cohorts are required.
Recently, NP levels have been shown to be
modulated by medication. The relationship betwe-
en a drop in NP level and the improvement of symp-
toms suggests that NP tailored therapy may be an
attractive approach in future.
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